The thrombospondin1-TGF-beta axis in multiple myeloma

多发性骨髓瘤中的血小板反应蛋白 1-TGF-β 轴

• 批准号: 8893914
• 负责人: JOANNE E MURPHY-ULLRICH
• 金额: $ 59.83万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2019-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8893914
• 关键词: Address; Adverse effects; Adverse event; Back; Binding; Biological Availability; Bone Diseases; Bone Marrow; Bone Marrow Cells; Bone remodeling; Bortezomib; Cell Line; Cell Surface Receptors; Cell physiology; Cells; Chronic; Clinical Trials; Coculture Techniques; Data; Dendritic Cells; Development; Dexamethasone; Disease; Dose; Drug Combinations; Drug Kinetics; Drug Targeting; Extracellular Matrix Proteins; Goals; Growth Factor; Half-Life; Health; Hematopoietic; Heterogeneity; Hour; Human; Immune; Immune System Diseases; Immune system; Immunocompetent; In Vitro; Inflammation; Insulin-Like Growth Factor I; Interleukin-6; Lead; Leu-Ser-Lys-Leu peptide; Ligands; Malignant Neoplasms; Mediating; Metabolic; Modeling; Modification; Morbidity - disease rate; Multiple Myeloma; Mus; Oral; Osteoblasts; Osteoclasts; Osteolytic; Pathogenesis; Pathway interactions; Peptides; Performance; Pharmaceutical Preparations; Phosphotransferases; Plasma; Plasma Cells; Pre-Clinical Model; Production; Property; Regulation; Risk; Role; SCID Mice; Stromal Cells; T-Cell Development; T-Lymphocyte Subsets; TNFSF11 gene; Therapeutic; Toxic effect; Transforming Growth Factor beta; Transforming Growth Factors; Tumor Burden; Vascular Endothelial Growth Factors; Work; angiogenesis; base; bone cell; carcinogenesis; cytokine; drug development; improved; in vivo; inhibitor/antagonist; mimetics; mouse model; novel; novel strategies; osteoblast differentiation; peptidomimetics; pre-clinical; receptor; small molecule

DESCRIPTION (provided by applicant): Multiple myeloma (MM) is an incurable cancer of plasma cells that is dependent on the bone marrow microenvironment for progression. Transforming growth factor-beta (TGF-ß) is a multi-functional growth factor elaborated by MM cells and by cells in the bone marrow microenvironment. TGF-ß stimulates MM progression through promotion of catabolic bone remodeling, IL-6 secretion, and Th17 T cell development, leading to osteolytic bone disease and immune dysregulation. Despite the importance of TGF-ß in MM, there are no clinical trials of TGF-ß antagonists for the treatment of MM. Most TGF-ß antagonists broadly target the ligand, receptors, or downstream kinases, which can antagonize homeostatic levels of TGF-ß and increase the risk of adverse events. We have developed a novel approach to selectively targeting disease-related TGF-ß activity in the MM bone marrow microenvironment through targeting only the TGF-ß which is activated through binding to the extracellular matrix protein, thrombospondin1 (TSP1). TSP1 is a secreted and extracellular matrix protein, which controls TGF-ß activity in disease by binding and activating latent TGF-ß. TSP1 is increased in MM. Our studies show that TSP1 activates latent TGF-ß expressed by human and mouse MM cells in vitro and importantly, a tetrapeptide antagonist (LSKL) of TSP1-dependent TGF-ß activation reduces MM tumor burden, stromal IL-6, and osteolytic bone disease in mouse models of MM. LSKL nearly completely blocks active TGF-ß in bone marrow cells of treated MM mice, indicating that the TSP1-TGF-ß antagonist peptide is working through targeting TSP1-dependent TGF-ß activation in the bone marrow microenvironment. These data establish that TSP1 is an important regulator of TGF-ß activity in MM and suggest that blockade of this pathway represents a novel and selective therapeutic strategy to reduce MM progression and bone disease. Our goal is to develop an orally available, "druggable" form of the LSKL peptide for treatment of MM. We have identified a lead compound (SRI31277) based on LSKL which has dose-dependent in vivo activity in a mouse model of MM, improved pharmacokinetics and oral bioavailability, and which will be the basis for identification and optimization of lead drugs. This proposal will combine mechanistic studies (Aim 1) with drug development efforts (Aim 2) to achieve our goal of identifying an orally active lead compound for treatment of MM. In Aim 1, we will further determine the role of the TSP1-TGF-ß pathway in MM through use of immune competent and TSP1 null models, by comparison of SRI31277 to global TGF-ß inhibitors and by use in drug combinations, and by complementary in vitro studies to define the TSP1 receptor on MM cells for TGF-ß activation and the role of this pathway in MM cell cytokine production and osteoblast/osteoclast regulation. The key goal of Aim 2 is to identify an orally active derivative of SRI31277 and a back-up peptide mimetic/small molecule suitable for GLP-IND enabling studies using both peptide and peptidomimetic/small molecule approaches.

描述（由申请人提供）：多发性骨髓瘤（MM）是一种无法治愈的浆细胞癌症，其进展依赖于骨髓微环境。转化生长因子-β（TGF-β）是由MM细胞和骨髓微环境中的细胞加工的多功能生长因子。TGF-β通过促进分解代谢骨重塑、IL-6分泌和Th 17 T细胞发育刺激MM进展，导致溶骨性骨病和免疫失调。尽管TGF-β在MM中的重要性，但是没有TGF-β拮抗剂用于治疗MM的临床试验。大多数TGF-β拮抗剂广泛靶向配体、受体或下游激酶，其可以拮抗TGF-β的稳态水平并增加不良事件的风险。我们已经开发了一种新的方法，通过仅靶向TGF-β 1来选择性靶向MM骨髓微环境中疾病相关的TGF-β 1活性，TGF-β 1通过与细胞外基质蛋白血小板反应蛋白1（TSP 1）结合而被激活。TSP 1是一种分泌的细胞外基质蛋白，其控制 通过结合和激活潜在的TGF-β 1在疾病中的活性。我们的研究表明，TSP 1在体外激活人和小鼠MM细胞表达的潜伏性TGF-β，重要的是，TSP 1依赖性TGF-β激活的四肽拮抗剂（LSKL）减少MM小鼠模型中的MM肿瘤负荷、基质IL-6和溶骨性骨病。LSKL几乎完全阻断治疗的MM小鼠骨髓细胞中的活性TGF-β，这表明TSP 1-TGF-β拮抗剂肽通过靶向骨髓微环境中的TSP 1依赖性TGF-β活化而起作用。这些数据证实了TSP 1是MM中TGF-β 1活性的重要调节因子，并表明阻断该途径代表了一种新的选择性治疗策略，可减少MM进展和骨疾病。我们的目标是开发一种口服的，“可药用”形式的LSKL肽治疗MM。我们已经确定了一种先导化合物（SRI 31277）的基础上LSKL的剂量依赖性的体内活性在小鼠模型的MM，改善的药代动力学和口服生物利用度，这将是基础上的识别和优化的先导药物。该提议将联合收割机机制研究（目标1）与药物开发努力（目标2）结合，以实现我们鉴定用于治疗MM的口服活性先导化合物的目标。在目标1中，我们将通过使用免疫活性和TSP 1无效模型，通过将SRI 31277与整体TGF-β抑制剂进行比较并通过在药物组合中使用，并通过补充的体外研究来确定MM细胞上用于TGF-β活化的TSP 1受体以及该途径在MM细胞细胞因子产生和成骨细胞/破骨细胞调节中的作用。目的2的关键目标是使用肽和肽模拟物/小分子方法鉴定SRI 31277的口服活性衍生物和适用于GLP-IND使能研究的备用肽模拟物/小分子。